686 related articles for article (PubMed ID: 20739054)
21. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
[TBL] [Abstract][Full Text] [Related]
22. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).
Boyers D; Jia X; Crowther M; Jenkinson D; Fraser C; Mowatt G
Health Technol Assess; 2011 May; 15 Suppl 1():23-32. PubMed ID: 21609650
[TBL] [Abstract][Full Text] [Related]
23. Safety and Efficacy of Eltrombopag in Children and Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis.
Kolanis S; Vasileiou E; Hatzipantelis E; Economou M; Tragiannidis A
Cardiovasc Hematol Agents Med Chem; 2021; 19(1):83-92. PubMed ID: 32914722
[TBL] [Abstract][Full Text] [Related]
24. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
[TBL] [Abstract][Full Text] [Related]
25. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study.
Frey N; Jang JH; Szer J; Illés Á; Kim HJ; Ram R; Chong BH; Rowe JM; Borisenkova E; Liesveld J; Winer ES; Cherfi A; Aslanis V; Ghaznawi F; Strickland S
Lancet Haematol; 2019 Mar; 6(3):e122-e131. PubMed ID: 30704923
[TBL] [Abstract][Full Text] [Related]
26. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.
Tomiyama Y; Miyakawa Y; Okamoto S; Katsutani S; Kimura A; Okoshi Y; Ninomiya H; Kosugi H; Nomura S; Ozaki K; Ikeda Y; Hattori T; Katsura K; Kanakura Y
J Thromb Haemost; 2012 May; 10(5):799-806. PubMed ID: 22409309
[TBL] [Abstract][Full Text] [Related]
27. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Dmytrijuk A; Robie-Suh K; Rieves D; Pazdur R
Oncology (Williston Park); 2009 Nov; 23(13):1171-7. PubMed ID: 20043468
[TBL] [Abstract][Full Text] [Related]
28. Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.
Özdemirkıran F; Payzın B; Kiper HD; Kabukçu S; Akgün Çağlıyan G; Kahraman S; Sevindik ÖG; Ceylan C; Kadıköylü G; Şahin F; Keskin A; Arslan Ö; Özcan MA; Kabukçu G; Görgün G; Bolaman Z; Büyükkeçeci F; Bilgir O; Alacacıoğlu İ; Vural F; Tombuloğlu M; Gökgöz Z; Saydam G
Turk J Haematol; 2015 Dec; 32(4):323-8. PubMed ID: 25914025
[TBL] [Abstract][Full Text] [Related]
29. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia.
Haselboeck J; Kaider A; Pabinger I; Panzer S
Thromb Haemost; 2013 Apr; 109(4):676-83. PubMed ID: 23389750
[TBL] [Abstract][Full Text] [Related]
30. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
[TBL] [Abstract][Full Text] [Related]
31. A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients.
Mei H; Xu M; Yuan G; Zhu F; Guo J; Huang R; Qin J; Lv T; Qin F; Cai H; Yin P; Qin T; Hu Y
Br J Haematol; 2021 Dec; 195(5):781-789. PubMed ID: 34528239
[TBL] [Abstract][Full Text] [Related]
32. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
33. Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia.
Wu K; Thapar M; Farrell C; Hayes S; Guo H; Hou M; Zhang J
Clin Ther; 2015 Jul; 37(7):1382-95. PubMed ID: 25929594
[TBL] [Abstract][Full Text] [Related]
34. Eltrombopag for use in children with immune thrombocytopenia.
Kim TO; Despotovic J; Lambert MP
Blood Adv; 2018 Feb; 2(4):454-461. PubMed ID: 29487060
[TBL] [Abstract][Full Text] [Related]
35. [The efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia].
Huang YT; Liu XF; Chen YF; Fu RF; Liu W; Zhang L; Yang RC
Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):32-36. PubMed ID: 29551030
[No Abstract] [Full Text] [Related]
36. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.
Boyers D; Jia X; Jenkinson D; Mowatt G
Pharmacoeconomics; 2012 Jun; 30(6):483-95. PubMed ID: 22480381
[TBL] [Abstract][Full Text] [Related]
37. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.
Khelif A; Saleh MN; Salama A; Portella MDSO; Duh MS; Ivanova J; Grotzinger K; Roy AN; Bussel JB
Am J Hematol; 2019 Feb; 94(2):200-208. PubMed ID: 30417939
[TBL] [Abstract][Full Text] [Related]
38. Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura.
Chiou TJ; Chang YF; Wang MC; Kao CW; Lin HY; Chen TY; Hsueh EJ; Lan YJ; Sung YC; Lin SF; Bai LY; Chen CG
Transl Res; 2015 Dec; 166(6):750-761.e4. PubMed ID: 26477577
[TBL] [Abstract][Full Text] [Related]
39. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.
Kellum A; Jagiello-Gruszfeld A; Bondarenko IN; Patwardhan R; Messam C; Mostafa Kamel Y
Curr Med Res Opin; 2010 Oct; 26(10):2339-46. PubMed ID: 20735290
[TBL] [Abstract][Full Text] [Related]
40. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR
Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
